The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Dylan-hyde Tyler since 2017.
The trader's CIK number is 1682027.
At the time of the last reporting, Dylan-hyde Tyler was the Chief Legal Officer of Crispr Therapeutics Ag. (stock ticker symbol CRSP).
Also see all insider trading activities at Crispr Therapeutics Ag.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2018 | CRSP | 0 | $0 | 135,000 | $3,431,678 | 45,000 | $581,181 |
| 2017 | CRSP | 0 | $0 | 90,000 | $1,635,769 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-01-16 | CRSP | Sale | 66,000 | 28.11 | 1,855,458 |
| 2018-01-16 | CRSP | Option Ex | 21,000 | 12.57 | 263,970 |
| 2018-01-02 | CRSP | Option Ex | 8,000 | 12.57 | 100,560 |
| 2018-01-02 | CRSP | Sale | 38,000 | 23.15 | 879,700 |
| 2017-12-28 | CRSP | Option Ex | 700 | 14.43 | 10,101 |
| 2017-12-29 | CRSP | Sale | 30,300 | 22.48 | 681,295 |
| 2017-12-28 | CRSP | Sale | 700 | 21.75 | 15,225 |
| 2017-12-29 | CRSP | Option Ex | 15,300 | 13.50 | 206,550 |
| 2017-12-22 | CRSP | Sale | 15,000 | 20.55 | 308,250 |
| 2017-12-15 | CRSP | Sale | 15,000 | 18.90 | 283,500 |
| 2017-08-04 | CRSP | Sale | 477 | 18.55 | 8,848 |
| 2017-08-07 | CRSP | Sale | 13,210 | 18.56 | 245,204 |
| 2017-08-08 | CRSP | Sale | 1,313 | 18.60 | 24,421 |
| 2017-05-01 | CRSP | Sale | 1,852 | 16.61 | 30,754 |
| 2017-04-28 | CRSP | Sale | 4,912 | 16.62 | 81,637 |
| 2017-04-27 | CRSP | Sale | 13,527 | 16.84 | 227,794 |
| 2017-04-26 | CRSP | Sale | 3,200 | 16.76 | 53,641 |
| 2017-04-21 | CRSP | Sale | 3,010 | 17.02 | 51,221 |
| 2017-04-24 | CRSP | Sale | 3,522 | 16.44 | 57,898 |
| 2017-04-25 | CRSP | Sale | 4,800 | 16.87 | 80,990 |
| 2017-04-19 | CRSP | Sale | 7,240 | 18.04 | 130,587 |
| 2017-04-20 | CRSP | Sale | 2,937 | 17.37 | 51,024 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Dylan-hyde Tyler (Chief Legal Officer of Crispr Therapeutics Ag at the time of this reporting) see the Securities and Exchange Commission (SEC) website.